Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
The company also aims to reach more than 60 million patients by 2030 and launch its next obesity injectables starting next year.
- Novo Nordisk shares fell as much as 9% on Monday as CEO Mike Doustdar outlined new growth ambitions at a Capital Markets Day in London, including plans to launch more than five blockbuster drugs by 2030.
- Management faces pressure to navigate looming patent expirations for the active ingredient in Ozempic and Wegovy in the early 2030s, while analysts questioned the pricing power and dealmaking strategy during the event.
- Doustdar detailed a multi-year rollout for next-generation injectables, targeting a launch of CagriSema early next year, while the company aims to have at least five oral assets in clinical trials before the end of this year.
- With 7 million prescriptions achieved to date, Novo's oral Wegovy pill generates 90% of sales through direct cash-pay channels, while the company aims to reach more than 60 million patients globally by 2030.
- Restructuring has yielded 13,000 total employee departures—following an initial 9,000 cuts and 4,000 subsequent exits—as the company scales manufacturing tenfold to supply 15 million patients with oral obesity therapies by 2030.
49 Articles
49 Articles
Novo Nordisk Stock Drops 8% as 2030 Plan, CagriSema Data and M&A Strategy Take Focus
Novo Nordisk (NYSE: NVO) shares suffered their sharpest decline in months after the drugmaker’s long-term strategy failed to ease concerns about slowing growth, pricing pressure, and its reliance on semaglutide, even as fresh Phase 3 data gave investors a more favorable look at next-generation obesity candidate CagriSema. Novo’s U.S.-listed shares closed 7.96% lower at $39.80 on Monday, Sept.Visit Website
Novo Nordisk Targets Five Multi-Blockbusters by 2030 as Oral Wegovy Gains Traction
Novo Nordisk A/S (NYSE:NVO) outlined an updated strategy at its Capital Markets Day centered on diabetes and obesity, expansion into blood and endocrine disorders, liver disease and cardiovascular conditions, and a growing focus on consumer-facing prescription medicine channels. The company said it
DECRYPTAGE - Two years ago, the company's capitalization reached $1 trillion, but since then the company has fallen by 70%, with the laboratory having suffered several setbacks.
Coverage Details
Bias Distribution
- 48% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
